- Daiichi Sankyo's edoxaban meets its primary endpoint of non-inferiority to warfarin in a Phase 3 study of more than 8K patients with either acute symptomatic deep vein thrombosis, DVT, pulmonary embolism, or both.
- When administered after heparin therapy, edoxaban was just as effective at preventing new blood clots as warfarin and caused less bleeding.
- "Edoxaban will face intense competition when it reaches the market," one analyst tells Bloomberg, adding that if approved for both venous thromboembolism and atrial fibrillation, edoxaban could see sales of ¥40B by year-end 2018.
- Expected to face competition from edoxaban: Pfizer (PFE) and Bristol-Myers' (BMY) Eliquis, Boehringer Ingelheim's Pradaxa, and Johnson & Johnson (JNJ) and Bayer's (BAYZF.PK) Xarelto.
- See also: Goldman says edoxaban poses limited threat to Eliquis.
Daiichi Sankyo's edoxaban meets primary endpoint
Sep 1 2013, 15:18 ET